摘要:
A method for reducing blood glucose level increase is provided that includes: providing a reducer of blood glucose level increase, wherein the reducer comprises isomaltulose; having an individual ingest the reducer; and having the individual consume a carbohydrate having an α-1,6-glucosyl bond ratio of from 0% to less than 50% relative to the total bonds among constituent saccharides, wherein the reducer is ingested before or after or simultaneously with consuming the carbohydrate, and wherein the reducer reduces an increase in the individual's blood glucose level caused by consuming the carbohydrate. The reducer of blood glucose level increase includes isomaltulose (PALATINOSE™) as an active ingredient so that when the reducer is ingested and a carbohydrate having an α-1,6-glucosyl bond ratio of from 0% to less than 50% relative to the total bonds among constituent saccharides is consumed, an increase in blood glucose level caused by ingesting the carbohydrate is reduced.
摘要:
It has now been found that after administration to a diseased person or person that is at risk for developing such disease of a neutraceutical or pharmaceutical composition that comprises: a) a lipid fraction comprising at least one of docosahexaneoic acid (DHA), docosapentaenoic acid (DPA) and eicosapentaenoic acid (EPA); b) a protein fraction comprising proteinaceous material from non-human origin which provide at least cysteine and/or taurine; and c) a mineral fraction comprising at least one of manganese and molybdene, the health of these persons improves. Membrane function of several types of mammalian cells improves, which allows efficient treatment of immune related disorders, such as allergy, autoimmune diseases, cancer, cognitive dysfunction and other diseases of the nervous system, neuropathies, such as diabetic neuropathies and neuropathic pains, neuronal damage during insulin resistance, and gut diseases and support of the development of gut and lung function during growth or recovery.
摘要:
It has now been found that after administration to a diseased person or person that is at risk for developing such disease of a neutraceutical or pharmaceutical composition that comprises a) a lipid fraction comprising at least one of docosahexaneoic acid (DHA), docosapentaenoic acid (DPA) and eicosapentaenoic acid (EPA); b) a protein fraction comprising proteinaceous material from non-human origin which provide at least cysteine and/or taurine; and c) a mineral fraction comprising at least one of manganese and molybdene, the health of these persons improves. Membrane function of several types of mammalian cells improves, which allows efficient treatment of immune related disorders, such as allergy, autoimmune diseases, cancer, cognitive dysfunction and other diseases of the nervous system, neuropathies, such as diabetic neuropathies and neuropathic pains, neuronal damage during insulin resistance, and gut diseases and support of the development of gut and lung function during growth or recovery.
摘要:
The present invention relates to a method for preventing obesity later in life by administering a certain nutritional composition to an infant with the age between 0 and 36 months. The composition comprises linoleic and alpha-linolenic acid.
摘要:
The present invention is related to a functional food ingredient, which replaces sugar on a 1/1 weight and/or volume basis in food recipes containing sucrose, with a substantial caloric reduction in view. More than an ingredient, it has to be seen as a functional ingredient, since it possesses some health promoting effects. The functional food replacement for sucrose according to the present invention comprises prebiotic fibres and sweeteners, and possibly other non selective fibres, minerals, vitamins and probiotic strains.
摘要:
It has now been found that after administration to a diseased person or person that is at risk for developing such disease of a neutraceutical or pharmaceutical composition that comprises a/ a lipid fraction comprising at least one of docosahexanoic acid (DHA), docosapentaenoic acid (DPA) and eicosapentaenoic acid (EPA); b/ a protein fraction comprising proteinaceous material from non-human origin which provide at least cysteine and/or taurine; and c/ a mineral fraction comprising at least one of manganese and molybdene, the health of these persons improves. Membrane function of several types of mammalian cells improves, which allows efficient treatment of immune related disorders, such as allergy, autoimmune diseases, cancer, cognitive dysfunction and other diseases of the nervous system, neuropathies, such as diabetic neuropathies and neuropathic pains, neuronal damage during insulin resistance, and gut diseases and support of the development of gut and lung function during growth or recovery.
摘要翻译:现在已经发现,给予患有疾病的患有疾病的患者或患有这样的药物组合物疾病疾病的人包括含有二十二碳六烯酸(DHA),二十二碳五烯酸(DPA)中的至少一种的脂质部分 )和二十碳五烯酸(EPA); b /一种蛋白质级分,其包含至少提供半胱氨酸和/或牛磺酸的来自非人源的蛋白质物质; 和c / a包含锰和钼中的至少一种的矿物部分,这些人的健康得到改善。 几种类型的哺乳动物细胞的膜功能得到改善,其允许有效治疗免疫相关疾病,例如过敏,自身免疫性疾病,癌症,认知功能障碍和其他神经系统疾病,神经病,如糖尿病性神经病和神经性疼痛,神经元损伤 在胰岛素抵抗期间,肠道疾病和支持生长或恢复期间肠和肺功能的发展。
摘要:
The present invention relates to formulations containing isomaltulose and a polyphenol-containing composition, uses of same and the use of isomaltulose for masking unwanted taste components, in particular bitter substances, in formulations, in particular in formulations containing tea extracts.
摘要:
The present invention relates to the use of isomaltulose as a taste-decreasing (e.g., aftertaste-reducing) agent, and to sweetener mixtures in which isomaltulose decreases the duration of taste by, for example, reducing the duration of aftertaste.
摘要:
The invention provides an agent comprising palatinose, for enhancing appearance of null wave, particularly, null 1 wave, and inducing a relaxed state to thereby promote alleviation or relief of mental stress or tense.
摘要:
An antiobestic agent of the present invention having antiobestic effect, carbohydrase inhibitory effect, blood sugar increase inhibitory effect, monosaccharide absorption inhibitory effect, cholic acid adsorptive excretion promoting effect, cholesterol lowering effect, blood triglyceride lowering effect and lipase inhibitory effect and being useful not only as an antiobestic agent but also as an antilipotrophic agent, an antihyperlipemic agent, an antiarteriosclerotic agent and an antidiabetic agent. Tamarind seed coat extract containing a large amount of procyanidin, which is a trimer represented by the following formula and serves as the active ingredient in the present invention, exhibits a potent antiobestic effect as such without the need for further purification. The antiobestic agent of the present invention is usable as a carbohydrase inhibitor, a blood sugar increase inhibitor, a monosaccharide absorption inhibitor, a cholic acid adsorptive excretion promoter, a cholesterol lowering agent, a blood triglyceride lowering agent and a lipase inhibitor. Moreover, use of the antiobestic agent makes it possible to produce foods or beverages and animal feeds having these effects, thus contributing to the relief or prevention of diabetes and obesity in our daily life